(2-(甲基硫代)吡啶-3-基)甲醇 | 62658-90-6

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 中文名称: (2-(甲基硫代)吡啶-3-基)甲醇
• 英文名称: 3-Methanol-2-thiomethyl-pyridin
• 英文别名: 3-hydroxymethyl-2-methylthiopyridine；(2-methylsulfanylpyridin-3-yl)methanol
• CAS: 62658-90-6
• 化学式: C₇H₉NOS
• 分子量: 155.221
• InChiKey: UTKCWZWWIQFORB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  58.4
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  (2-(甲基硫代)吡啶-3-基)甲醇 在 氯化亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 2-methylthio-3-chloromethylpyridine
  参考文献：
  名称：

  Identification of MK-944a:  A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors

  摘要：

  Recent results from human clinical trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). However, the emergence of viral resistance, demanding treatment protocols, and adverse side effects have exposed the urgent need for a second generation of HIV protease inhibitors. The continued exploration of our hydroxylaminepentanamide (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the identification of Crixivan (indinavir sulfate, MK-639, L-735,524), has now yielded MK-944a (L-756,423). This compound is potent, is selective, and competitively inhibits HIV-1 PR with a Ki value of 0.049 nM. It stops the spread of the HIVIIIb-infected MT4 lymphoid cells at 25.0-50.0 nM, even in the presence of alpha(1) acid glycoprotein, human serum albumin, normal human serum, or fetal bovine serum. MK-944a has a longer half-life in several animal models (rats, dogs, and monkeys) than indinavir sulfate and is currently in advanced human clinical trials.

  DOI：

  10.1021/jm9903848
• 作为产物：
  描述：

  2-甲硫基烟酸 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 氯仿 为溶剂， 反应 1.0h， 生成 (2-(甲基硫代)吡啶-3-基)甲醇
  参考文献：
  名称：

  Identification of MK-944a:  A Second Clinical Candidate from the Hydroxylaminepentanamide Isostere Series of HIV Protease Inhibitors

  摘要：

  Recent results from human clinical trials have established the critical role of HIV protease inhibitors in the treatment of acquired immune-deficiency syndrome (AIDS). However, the emergence of viral resistance, demanding treatment protocols, and adverse side effects have exposed the urgent need for a second generation of HIV protease inhibitors. The continued exploration of our hydroxylaminepentanamide (HAPA) transition-state isostere series of HIV protease inhibitors, which initially resulted in the identification of Crixivan (indinavir sulfate, MK-639, L-735,524), has now yielded MK-944a (L-756,423). This compound is potent, is selective, and competitively inhibits HIV-1 PR with a Ki value of 0.049 nM. It stops the spread of the HIVIIIb-infected MT4 lymphoid cells at 25.0-50.0 nM, even in the presence of alpha(1) acid glycoprotein, human serum albumin, normal human serum, or fetal bovine serum. MK-944a has a longer half-life in several animal models (rats, dogs, and monkeys) than indinavir sulfate and is currently in advanced human clinical trials.

  DOI：

  10.1021/jm9903848

文献信息

• 4-(2-Chloro- or
  申请人：Societe Anonyme Dite : Hexachimie

  公开号：US04096270A1

  公开（公告）日：1978-06-20

  This invention relates to substituted 1,4-dihydropyridines showing interesting physiological activities, particularly on the cardiovascular system. 1,4-Dihydropyridines in accordance with the invention are substituted in the 4-position by a 2-chloropyrid-3-yl or a 2-methylthiopyrid-3-yl group, in the 3- and 5-positions by a methoxycarbonyl or ethoxycarbonyl group and in the 2- and 6-positions by a methyl group. Acid addition salts of these compounds are included in the present invention. The compounds can be prepared by reacting an appropriate 2-substituted nicotinaldehyde with an alkyl acetoacetate. Compounds in accordance with the invention have shown anti-hypertensive activity at very low doses.

  本发明涉及替代的1,4-二氢吡啶，具有有趣的生理活性，特别是对心血管系统的影响。本发明中的1,4-二氢吡啶在4位被2-氯吡啶-3-基或2-甲硫基吡啶-3-基取代，在3和5位被甲氧羰基或乙氧羰基取代，在2和6位被甲基取代。这些化合物的酸盐也包括在本发明中。这些化合物可以通过将适当的2-取代烟醛和烷基乙酮酸酯反应制备而成。根据本发明的化合物在非常低的剂量下表现出降压活性。
• Chemokine receptor binding heterocyclic compounds
  申请人：——

  公开号：US20040220207A1

  公开（公告）日：2004-11-04

  Novel compounds that are useful for targeting chemokine receptors are disclosed. These compounds are complex tertiary amines.

  本发明揭示了用于靶向趋化因子受体的新化合物。这些化合物是复杂的三级胺。
• Alpha-unsaturated amines, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP0302389A2

  公开（公告）日：1989-02-08

  α-Unsaturated amines of the formula: wherein X¹ and X² are such that one is an electron-­attracting group with the other being a hydrogen atom or an electron-attracting group; R¹ is a group attached through a nitrogen atom; R² is a hydrogen atom or a group attached through a carbon, nitrogen or oxygen atom; n is an integer equal to 0, 1 or 2; A is a heterocyclic group or a cyclic hydrocarbon group, and salts thereof and their agrochemical use as insecticidal and/or miticidal agents are described.

  式中α-不饱和胺： 式中：X¹和X²一个是引电子基团，另一个是氢原子或引电子基团；R¹是通过氮原子连接的基团；R²是氢原子或通过碳原子、氮原子或氧原子连接的基团；n是等于0、1或2的整数；A是杂环基团或环烃基团；描述了其盐类及其作为杀虫剂和/或杀螨剂的农用化学品用途。
• Intermediates, their production and their use for preparing alpha-unsaturated amines
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0529680A2

  公开（公告）日：1993-03-03

  α-unsaturated amines of the formula: wherein X¹ and X² are such that one is an electron-attracting group with the other being a hydrogen atom or an electron-attracting group; R¹ is a group attached through a nitrogen atom; R² is a hydrogen atom or a group attached through a carbon, nitrogen or oxygen atom; n is an integer equal to 0, 1 or 2; A is a heterocyclic group or a cyclic hydrocarbon group, and salts thereof and their agrochemical use as insecticidal and/or miticidal agents are described.

  式中α-不饱和胺： 其中，X¹和X²一个是引电子基团，另一个是氢原子或引电子基团；R¹是通过氮原子连接的基团；R²是氢原子或通过碳原子、氮原子或氧原子连接的基团；n是等于0、1或2的整数；A是杂环基团或环烃基团。
• CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS
  申请人：ANORMED INC.

  公开号：EP1317445B1

  公开（公告）日：2009-03-11